Anavex Life Sciences
 | |
| Public OTCQB: AVXL | |
| Industry | Biopharmaceuticals |
| Headquarters | New York, New York, USA |
Key people |
Christopher U. Missling, MS, PhD, MBA, President and CEO Tom Skarpelos, Director Michael Gold, MD, Scientific Advisory Board Ottavio Arancio, MD, PhD, Scientific Advisory Board Tangui Nicolas Maurice, Ph.D., Scientific Advisory Board Paul Aisen, MD, Scientific Advisory Board – Clinical Expert Jeffrey Cummings, MD, Scientific Advisory Board – Clinical Expert |
| Website | anavex.com |
Anavex Life Sciences Corp. is a pharmaceutical company that develops drug candidates.
ANAVEX 2-73 has been shown to provide protection from oxidative stress, which damages and destroys neurons and is believed to be a primary cause of Alzheimer's disease. Research in recent years indicates that oxidative stress is a precursor to amyloid-beta plaques and tau (see also Neuro-Fibrillary Tangles), and could be a novel and appropriate therapeutic target.[1]
See also
- Clinical trial
- Drug development
- Pharmaceutical company
- Pre-clinical development
References
- ↑ Nunomura A, Castellani RJ, Zhu X, Moreira PI, Perry G, Smith MA (July 2006). "Involvement of oxidative stress in Alzheimer disease". J. Neuropathol. Exp. Neurol. (Review) 65 (7): 631–41. doi:10.1097/01.jnen.0000228136.58062.bf. PMID 16825950.